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Simple Summary: Glioblastoma, the brain tumour with highest prevalence and lethality, exhibits a
characteristic glycolytic phenotype with increased lactate production. Recently, we reported a MCT1
overexpression in GBMs tumours, being associated to tumour growth and aggressiveness. Thus, we
aimed to disclose the role of MCT1 in GBM prognosis and in vivo therapy response. Importantly,
MCT1 overexpression is associated with poor prognosis of GBM. Moreover, MCT1 inhibition retards
GBM tumour growth and boosts response to temozolomide treatment.
Abstract: Background: Glioblastomas (GBMs) present remarkable metabolism reprograming, in which
many cells display the “Warburg effect”, with the production of high levels of lactate that are extruded
to the tumour microenvironment by monocarboxylate transporters (MCTs). We described previously
that MCT1 is up-regulated in human GBM samples, and MCT1 inhibition decreases glioma cell
viability and aggressiveness. In the present study, we aimed to unveil the role of MCT1 in GBM
prognosis and to explore it as a target for GBM therapy in vivo. Methods: MCT1 activity and protein
expression were inhibited by AR-C155858 and CHC compounds or stable knockdown with shRNA,
respectively, to assess in vitro and in vivo the effects of MCT1 inhibition and on response of GBM
to temozolomide. Survival analyses on GBM patient cohorts were performed using Cox regression
and Log-rank tests. Results: High levels of MCT1 expression were revealed to be a predictor of
poor prognosis in multiple cohorts of GBM patients. Functionally, in U251 GBM cells, MCT1 stable
knockdown decreased glucose consumption and lactate efflux, compromising the response to the
MCT1 inhibitors CHC and AR-C155858. MCT1 knockdown significantly increased the survival of
orthotopic GBM intracranial mice models when compared to their control counterparts. Furthermore,
MCT1 downregulation increased the sensitivity to temozolomide in vitro and in vivo, resulting in
significantly longer mice survival. Conclusions: This work provides first evidence for MCT1 as a new
prognostic biomarker of GBM survival and further supports MCT1 targeting, alone or in combination
with classical chemotherapy, for the treatment of GBM.
Keywords: monocarboxylate transporters; glioblastoma; lactate; Warburg effect; prognostic biomarker
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1. Introduction
Glioblastoma (GBM) is the most common and most lethal primary brain tumour
in adults. Current treatment includes surgery, radiotherapy, and chemotherapy with the
alkylating agent temozolomide (TMZ) [1], but despite treatment, the prognosis of patients is
very dismal, with a median overall survival (OS) of approximately 15 months [2]. Critically,
these figures have not changed significantly for decades, highlighting an urgent unmet
need to develop novel therapeutic strategies for this cancer. To do so, it is crucial to identify
novel clinically relevant biomarkers predictive of patient outcome and to explore how they
can be therapeutically targeted.
Most cancer cells present a dynamic metabolic reprogramming, particularly on cellular
energetics, displaying high glycolytic rates coupled with lactate production, even in the
presence of normal levels of oxygen (Warburg effect). This has been recognized as an
important hallmark of cancer [3], and confers advantages to cancer cells, including growth,
survival and aggressiveness [4–6]. Concordantly, GBMs present increased glucose uptake
compared to a normal brain [7], and ~90% of all glucose consumed by GBM cells is con-
verted into lactate or alanine, which contributes to the remarkable infiltrative phenotype of
GBM cells into the surrounding non-neoplastic tissue [8]. In this context, monocarboxylate
transporters (MCTs) play an important role in the maintenance of high cancer cell gly-
colytic rates, contributing to acidification of the extracellular tumour microenvironment
due to the proton-coupled mechanism of lactate transport [9]. The MCT family comprises
14 members with similar topology, but only the first four isoforms (MCT1-4) use lactate
as common substrate [10–15]. Besides lactate, these MCT isoforms also mediate the trans-
membrane transport of other monocarboxylic acids, including pyruvate and ketone bodies
(acetoacetate and D-β-hydroxybutyrate) [15]. MCTs have crucial roles in mammalian cell
metabolism, are critical for metabolic communication between cells [11,16], and therefore
present different kinetic characteristics and tissue distribution [10,13,17]. MCT1, MCT2,
and MCT4 play a crucial role in the brain energetics, in the so called “astrocyte-neuron
lactate shuttle”. Lactate produced by astrocytes leaves the cell through the activity of
both MCT1 and MCT4, which is then utilized by neurons whose uptake is mediated by
MCT2 [18]. The activity of these transporters in the brain has been demonstrated to play a
role in learning and memory [19].
Upregulation of MCTs, especially MCT1 and MCT4, has been increasingly reported
in different human solid tumours, demonstrating the importance of MCTs in cancer bi-
ology [20]. MCT1 and MCT4 overexpression has also been described in gliomas, being
MCT1 isoform the most prevalent plasma membrane transporter responsible for lactate
efflux [21,22]. We previously described the role of MCT1 in glioma cell survival and aggres-
siveness using in vitro and ex vivo models [21,23]. Other studies reported the potential of
MCT1 targeting in reversing the cell growth and aggressiveness of several other malignant
tumours, namely in diffuse large B cell lymphoma [24], oesophageal squamous cell carci-
noma [25], breast [26], lung [27], and bladder cancer [28]. Thus, while MCTs are generally
viewed as promising anticancer targets, additional studies are needed to clearly establish
the prognostic value of MCTs in patients, and to support the therapeutic value of lactate
transport inhibition in GBM. In the present study, we show that high MCT1 expression
is a predictor of poor prognosis in multiple independent cohorts of GBM patients, estab-
lishing it as a novel biomarker. In addition, MCT1 knockdown reduces lactate efflux and
cell aggressiveness in vitro and, more importantly, significantly increased the survival of
orthotopic glioma in in vivo mice models. Critically, and from a translational perspective,
MCT1 knockdown significantly increased the sensitivity of GBM cells to TMZ in vitro and
in vivo, clearly extending the survival of mice.
2. Materials and Methods
2.1. Cells and Culture Conditions
U251 cells were kindly provided by Professor Joseph Costello, University of California,
San Francisco, CA, USA. Cell line authentication was performed by IdentiCell Laboratories
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(Department of Molecular Medicine (MOMA) at Aarhus University Hospital Skejby in
Århus, Denmark). Genotyping confirmed the complete identity of the cell line. Cells were
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM 1×, High Glucose; Gibco,
Invitrogen, USA) supplemented with 10% Foetal Bovine Serum (FBS; Gibco, Invitrogen)
and 1% penicillin/streptomycin solution (Gibco, Invitrogen, Waltham, MA, USA), at 37 ◦C
and 5% CO2.
2.2. Generation of Stable shMCT1 Expressing Cells
For the generation of U251 cells stably expressing shMCT1, a pool of target-specific
lentiviral vector plasmids each encoding 19–25 nt (plus hairpin) shRNAs to MCT1 knock-
down (sc-37235-SH, Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used. Transfec-
tion was done by using the FUGENE HD reagent (Roche, Switzerland), as recommended
by the manufacturer. Cells were plated on 12 well plates until 80% of confluence and
transfected in DMEM medium with FBS without antibiotic addition, for 24 h. After that,
stable transfectants were selected with 1µg/mL puromycin for one month. The empty
vector was also transfected as a control. For clone isolation, 200 U251 shMCT1 and U251
shCTRL cells were plated in a 100 mm plate and several clones were collected, expanded,
and analysed for MCT1 expression by Western blot.
2.3. Drugs
Alpha-cyano-4-hydroxycinnamate (CHC; Sigma-Aldrich, St. Louis, MO, USA), Temo-
zolomide (TMZ, Sigma-Aldrich), and AR-C155858 compound (R&D systems, Minneapolis,
MN, USA) were dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich, St. Louis, MO,
USA) to 3 M, 100 mM, and 3 mM stock solutions, respectively.
2.4. Antibodies
The following antibodies and conditions were used for immunofluorescence (IF) and
Western blot (WB) assays: MCT1 ((AB3538P, Chemicon International, MERCK, Germany
(IF); 1:200), (H-1, sc-365501, Santa Cruz Biotechnology, USA (WB); 1:500)); MCT4 (H-90,
sc-50329, Santa Cruz Biotechnology, USA; 1:500); hypoxia-inducible factor 1α (HIF-1α)
(610958, BD Biosciences, Germany; 1:100 dilution (IF); 1:500 dilution (WB)), carbonic
anhydrase IX (CAIX) (Abcam, UK, 1:2000), and hexokinase II (HKII) (Abcam, UK, 1:750).
2.5. GBM Patient Cohorts and Survival Analysis
The Cancer Genome Atlas (TCGA) data [29] was accessed through the GDC portal
(https://portal.gdc.cancer.gov/), as explained in [30], to obtain MCT1 microarray expres-
sion data from GBM (n = 572) and LGG (lower grade glioma, WHO grades II and III)
patients (n = 27), and non-cancer unmatched samples (n = 10). GBM patient clinical data
was also collected. MCT1 expression and clinical data from Rembrandt (n = 203) [31],
Ducray (n = 52) [32], Lee Y (n = 191) [33], Murat (n = 80) [34], Gravendeel (n = 159) [35], Joo
(n = 54) [36], and Nutt (n = 28) [37] patient GBM datasets were also obtained, as previously
described [30]. The maximally selected rank statistics [38] were used to determine an
optimal cut-off for the survival analysis, as provided in the ‘survminer’ package.
2.6. Western Blot
Western blot was performed as described previously [19]. Primary antibodies were
incubated overnight at 4 ◦C and bound antibodies were detected by chemiluminescence
(Supersignal West Femto kit; Pierce, Thermo Scientific, Waltham, MA, USA) (Figure S1).
β-Actin or tubulin were used as loading controls.
2.7. Immunofluorescence
Cells were grown on glass coverslips at a density of 2 × 104 cells/well and incubated
at 37 ◦C and 5% CO2 overnight. Then, cells were incubated in DMEM without FBS for
24 h. Immunofluorescence was performed as previously described [26]. Briefly, slides
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were incubated with the primary antibodies (room temperature, overnight), and then
incubated with the secondary antibody anti-rabbit-Alexa Fluor 488 (A11008, Invitrogen,
Waltham, MA, USA, 1:500) for 1 h in 5% BSA (MCT4 and MCT1), or the secondary antibody
anti-rabbit-Alexa Fluor 594 (A11032, Invitrogen USA, 1:250) (HKII and HIF-1α). Images
were acquired by a fluorescence microscope (Olympus IX81) with the Cell P software.
2.8. Cell Metabolism Assays
Cells were plated in 48 well plates at a density of 3 × 104 cell per well. Then, they
were cultured in DMEM at 4.5 g/L glucose without FBS, untreated or in the presence
of 10 mM CHC. Glucose and lactate contents in the cell culture media were quantified
after 24 h and 48 h, with the commercial kits Spinreact, Spain and Roche, Switzerland
respectively), as described in [21]. Results are shown as total µg/total biomass, assessed by
the sulforhodamine B assay (SRB, TOX-6, Sigma-Aldrich, USA).
2.9. Cell Viability Assay
To determine the response of U251 shMCT1 knockdown to CHC, AR-C155858, and
TMZ, cell viability was estimated using the Sulphorhodamine B assay, following the
manufacturer’s instructions, as described in [26]. U251 shMCT1 and U251 shCTRL cells
were plated into 96-well plates, at a density of 3 × 103 cells/well, in DMEM medium,
and treated with different concentrations of CHC or AR-C155858 for 24 h, 48 h, and 72 h.
Additionally, TMZ treatment was performed for 72 h, as well as combinatory AR-C155858 +
TMZ treatment. Spectrophotometric measurements were done at 490 nm, using 655 nm as
reference absorbance (Tecan infiniteM200). Results represent the mean of three independent
experiments, each one in triplicate, and were analysed using the Graph Pad Software.
2.10. In Vivo Orthotopic GBM Xenografts
All animal experiments (immunocompromised NSG mice, NOD.Cg-Prkdcscid Il2rgtm1
Wjl/SzJ) were approved by the national ethical committee (Direção Geral de Alimentação
e Veterinária, Portugal) and were performed in accordance with the European Union
Directive 2010/63/EU. For intracranial models, a total of 5 × 105 U251 cells, namely
U251 shCTRL (n = 11) and U251 shMCT1 (n = 11), were injected in the brain striatum
(1.8 mm medial-lateral right, 0.1 mm anterior-posterior, and 2.5 mm dorsal-ventral from
the bregma) of 2–6 months aged mice as previously described [30]. TMZ treatment of
U251 shCTRL (n = 5) and U251 shMCT1 (n = 5) mice started at day 15 after U251 cells
implantation. Each mouse was treated daily with 50 mg/kg TMZ by oral gavage, in
2 cycles (5 days ON, 3 days OFF) [39]. Animal body weight was assessed 3 times a week,
and general behaviour and symptomatology was evaluated daily. Mice were sacrificed
when body weight reached ≤70% of their maximum body weight, perfused with saline
solution followed by PFA 4%, and whole brains were collected and paraffin embedded for
subsequent immunohistochemistry analyses.
2.11. Immunohistochemistry
MCT1, MCT4, CAIX and Ki67 protein expression for U251 shMCT1 and U251 shCTRL
tumours collected from NSG mice were evaluated by immunohistochemistry (IHC). IHC
for MCT1 was performed using UltraVision LP detection system HRP Polymer (Thermo
Fisher Scientific, Waltham, MA, USA), and for MCT4, CAIX and Ki67 using UltraVision
Large Volume Detection System Anti-Polyvalent, HRP (Thermo Fisher Scientific), as previ-
ously described [21,23]. Briefly, deparaffinised and rehydrated slides were submitted to
heat-induced antigen retrieval for 20 min at 98 ◦C with 10 mM citrate buffer (pH 6.0). After
endogenous peroxidase inactivation, incubation with the primary antibody was performed
overnight for MCT1, and during 2 h for MCT4, CAIX and Ki67, at room temperature.
The immune reactions were visualized with 3,3′-diamonobenzidine (DAB + Substrate
System; Dako, Denmark) as a chromogen. The slides were counterstained with haema-
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toxylin and mounted with Entellan® (Merck-Millipore, Darmstadt, Germany). For each
immunoreaction, a positive control was included.
2.12. Statistical Analysis
The GraphPad prism 5 software was used for statistical analysis, with the Student
t test used for in vitro studies and log-rank test for mice survival analysis, considering
significant values p < 0.05. SPSS 22.0 software (SPSS, Inc., Chicago, IL, USA) was used
to evaluate the prognostic value of MCT1 in GBM patients by the log-rank test. Cox
proportional hazard model was used to perform multivariate analysis (in SPSS 25 software;
SPSS, Inc., Chicago, IL, USA), where the potential confounding effects of age and gender
were considered. Comprehensive Meta Analysis (CMA) software (Biostat, Inc., Englewood,
NJ, USA) was used to perform meta-analysis. For this, hazard ratios and 95% confidence
intervals were used. A random effects statistical model was applied.
3. Results
3.1. Increased MCT1 Expression Is a Predictor of Poor Prognosis in GBM Patients
A previous study from our group showed that MCT1 expression is associated with
growth and aggressiveness of GBM models [21], but its relevance as a potential prognostic
biomarker in patients remains unknown. Therefore, we started by investigating if MCT1
expression can be associated with the malignancy grade of gliomas and whether it is
predictive of the overall survival (OS) of GBM patients using a variety of independent
cohorts. We found that MCT1 expression increases significantly from normal brain samples
to LGG (lower grade glioma), and to GBM patients from TCGA (Figure 1A). Critically,
high MCT1 expression was significantly associated with a shorter OS of GBM patients
in the large TCGA cohort (Figure 1B). This prognostic value of MCT1 in GBM patients
was then consistently validated in seven additional cohorts of patients (Figure 1C–I). This
finding was then validated in the TCGA dataset (where other clinical information, such as
age and gender are available), using a multivariable Cox model, showing that MCT1-high
expression is associated with a shorter OS, independently of other prognostic variables,
including patient age and gender (Table 1). A meta-analysis including these eight datasets
showed that overall MCT1-high expression is associated with the shorter survival of GBM
patients (Figure 1J). Together, these data clearly establish MCT1 as a novel prognostic
biomarker with clinical relevance for GBM patients.
Table 1. Cox multivariable survival analysis in GBM patients from TCGA.
Parameters
Overall Survival (OS)
Hazard Ratio 95% CI
p-Value
MCT1 expression a 0.032 1.345 1.025–1.764
Age at diagnosis b <0.0001 1.827 1.499–2.226
Gender c 0.117 1.175 0.961–1.437
a MCT1-low (n = 71) vs. MCT1-high (n = 417) expression. b Age below average (average = 58; n = 237) vs. Age
above average (n = 251). c Female (n = 187) vs. Male (n = 301). Bold-faced values indicate significant p-values.
3.2. MCT1 Downregulation Alters GBM Cell Energetic Metabolism and Growth
In order to explore MCT1 as a therapeutic target in GBMs, we silenced MCT1 in
U251 cells. We confirmed U251 shMCT1 cells present very low levels of MCT1 expression,
as compared to shCTRL cells (Figure 2A). Importantly, this was not accompanied by
any compensatory increase in MCT4 expression (Figure 2A). Additionally, to evaluate
the effect of MCT1 downregulation on glycolytic and hypoxic phenotypes, HKII and
HIF-1α expression was assessed. U251 shMCT1 cells display a decreased expression of
HKII and HIF-1α proteins (Figure 2A), suggesting a reprogramming of the glycolytic
metabolic profile. Further, we also assessed their expression and cellular localization in
U251 shMCT1 by immunofluorescence (IF). Very low MCT1 expression in U251 shMCT1
was also confirmed by IF, while the levels of MCT4 expression in the plasma membrane
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were maintained regardless of MCT1 silencing (Figure 2B). The expression of nuclear
HIF-1α and cytoplasmic HKII also decreased in U251 shMCT1 cells (Figure 2B).




Figure 1. MCT1 is over-expressed in GBM patients and associates with poor prognosis. (A) MCT1 expression level in 10 
unmatched normal brains, 27 lower-grade gliomas (LGG), and 572 glioblastomas (GBM) patients from TCGA; *** p<0.001 
and **** p < 0.0001. (B–I) Kaplan-Meier survival curves of MCT1-low and MCT1-high GBM patients derived from micro-
array data from (B) TCGA dataset, n = 488, median OS 17.6 vs. 13.9 months, low vs. high MCT1 expression, respectively; 
p = 0.034; (C) REMBRANDT dataset, n = 178, median OS 541 vs. 390 days (p = 0.018); (D) Ducray dataset, n = 52, median 
OS 16.5 vs. 13.7 months (p = 0.043); (E) Lee Y dataset, n = 191, median OS 16.6 vs. 12.2 months (p = 0.018); (F) Murat dataset, 
n = 80, median OS 20.9 vs. 14.4 months (p = 0.003); (G) Gravendeel dataset, n = 155, median OS 13.3 vs. 7.8 months (p = 
0.000031); (H) Joo dataset, n = 54, median OS 28.4 vs. 16.9 months (p = 0.022); (I) Nutt dataset, n = 28, median OS 38.2 vs. 
9.1 months (p = 0.004); and (J) Forest plot of hazard ratios (HR), demonstrating the relationship between MCT1 expression 
and GBM patients’ overall survival. The HR for each cohort is represented by a black square (its size represents the weight 
of the study for the meta-analysis) and 95% confidence intervals (CI) by the extending lines. The estimated pooled effect 
is represented by a red diamond (HR = 1.670; 95% CI, 1.434–1.945; p < 0.0001). 
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Figure 2. Effect of MCT1 downregulation on cell metab lism. Expression of MCT1, MCT4, HKII and
HIF-1α in U251 shMCT1 cells by (A) Western Blot and (B) Immunofluorescence; Western blot MW:
HIF-1α 100 kDa, HKII 100 kDa, MCT1 50 kDa, MCT4 44 kDa and β-Actin 42 kDa; Repre ntative
pictures was taken at 400× magnification. (C) Glucose consumption and lactate production in MCT1
knockdown cells, up to 48 h; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001 U251 shCTRL vs.
U251 shMCT1. (D) Glucose consumption and lactate production in MCT1 knockdown cells treated
with CHC, up to 48 h; * p < 0.05 U251 shCTRL vs. U251 shCTRL + CHC (E) Glucose consumption
and lactate production in MCT1 knockdown cells treated with ARC155858, up to 48 h; ** p < 0.01;
*** p < 0.001 U251 shCTRL vs. U251 shCTRL + ARC155858. Results are representative of three
independent experiments, each in triplicate.
In what concerns the metabolic behaviour, there was a decrease in glucose uptake
and lactate release in U251 shMCT1 at 24 h and 48 h, as compared to control cells (U251
shCTRL; Figure 2C). Of note, MCT1 silencing rendered cells insensitive to the MCT1
inhibitors CHC (Figure 2D) and AR-C155858 (Figure 2E), since no alterations in lactate
release were observed, as opposed to U251 shCTRL cells (Figure 2D,E).
Furthermore, MCT1 downregulation decreased significantly cell growth over time
(Figure 3A), and decreased the sensitivity to CHC (as expressed by higher IC50 values),
compared to control cells (Figure 3B). Additionally, MCT1 downregulation rendered U251
shMCT1 cells insensitive to AR-C155858 at 48 h and 72 h (Figure 3C), validating MCT1 as
target. Globally, our data suggests that MCT1 silencing in GBM reduces the expression of
molecular mediators of glycolytic metabolism, resulting in impaired energetic metabolism
and insensitivity to pharmacological inhibitors of MCT1.
3.3. MCT1 Downregulation Increases Sensitivity to TMZ In Vitro and In Vivo, Increasing GBM
Mice Model Survival
We next investigated the role of MCT1 in the sensitivity of GBM cells to the standard-
of-care chemotherapeutic drug TMZ, using in vitro and in vivo experiments. Firstly, the
genetic downregulation of MCT1 in U251 shMCT1 cells significantly increased the sensitiv-
ity to TMZ, strikingly decreasing TMZ IC50 value from 778.2 µM to 75.78 µM (p = 0.0159;
Figure 4A). To further support these findings, a pharmacological approach targeting MCT1
was then tested in combination with TMZ treatment. Consistently, U251 shCTRL cells
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treated with MCT1 inhibitor AR-C155858 were significantly more sensitive to TMZ treat-
ment, while this enhanced effect was not observed in U251 shMCT1 cells (AR-C155858
+ TMZ IC50 values of 382.8 µM and 71.7 µM, respectively; Figure 4B). Additionally, no
effect was observed on TMZ response when U251 shMCT1 cells were treated with the
MCT1 specific inhibitor (300 nM AR-C155858) compared with TMZ alone (Figure 4C). An
important gene that is associated with TMZ sensitivity in GBM is the DNA-repair gene
O6-methylguanine–DNA methyltransferase (MGMT). Thus, in an attempt to explain the
increased sensitivity to TMZ upon MCT1 silencing, we investigated the expression of
MGMT in U251 cells. Importantly, U251 shMCT1 cells exhibited a decrease in MGMT
transcriptional levels (Figure S2A), but with no significant alterations at the MGMT protein
level (Figure S2B) when compared to U251 shCTRL cells.
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In order to confirm the potential prognostic value of MCT1 observed in GBM patients,
we established an intracranial orthotopic GBM xenograft model with U251 shCTRL and
U251 shMCT1 cells in NSG mice. Consistent with the patient data, we observed that
animals bea ing U251 shMCT1 tumours present a significant increase in OS compared to
U251 shCTRL tumours (median OS of 63.5 days and 43.5 days, respectively: Figure 5A).
Histopathological and IHC analysis for Ki67 showed a lower proliferative index for shMCT1
compared to shCTRL (Figure 5B). Long-term MCT1 knockdown in vivo was also confirmed
by IHC in the NSG mice U251 shMCT1 cell tumours (Figure 5C), while MCT4 expression
was similar between U251 shCTRL vs. shMCT1 (Figure 5C), consistent with the in vitro
findings (Figure 2A,B). Additionally, the effect of MCT1 downregulation on tumour hypoxia
markers was characterized by an assessment of expression of the HIF-1α downstream
target CAIX. In Figure C, it can be seen that CAIX expression decreased for NSG mice
U251 shMCT1 tumours compared to U251 shCTRL condition.
Having established the impact of MCT1 downregulation in treatment-naïve condi-
tions, we then tested the impact of MCT1 in the response of GBM to TMZ (orthotopic
int acranial GBM model). We found that animals bearing U251 hMCT1 tumours treated
with TMZ presented a prominent and statistically significant increased overall survival
(OS) as compared to U251 shCTRL TMZ-treated mice (Figure 5A). In addition, at the
experimental endpoint (206 days), all U251 shCTRL mice were dead, while four out of six
mice of U251 shMCT1 group were still alive and without any GBM-related weight loss
or neurological symptoms. Histopathological analysis revealed the absence of tumoural
masses in U251 shMCT1 group treated with TMZ (Figure 5B). The absence of Ki67 staining
observed in animals bearing U251 shMCT1 cells exposed to TMZ treatment support these
findings (Figure 5B). The absence of MCT1 and CAIX expression was confirmed in anim ls
bearing U251 shMCT1 cells with TMZ treatment (Figure 5C).
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4. Discussion
Glycolytic metabolism has recently been recognized as a fundamental mechanism in
the metabolic reprogramming of cancer cells [3]. The large amounts of glucose consumed
by tumou cells have bee use ul i the diagnosis of cancer using 18F-fluoro-2-de xy-D-
glucose positron emission tomography (18FDG PET) scanning, particularly in the detection
of metastases and recurrent disease, and to monitor therapy response [40]. To sustain the
glycolytic phenotype of tumour cells, several proteins are differentially expressed, like
proteins of the glycolysis pathway and some pH regulators, including MCTs [17,23].
GBM is the most prevalent and also the most aggressive malignant primary brain
tumour of the entral nervous s stem in adults [41]. These tumours present metabolic
reprogramming, with high glycolytic activity and consequent increased lactate produc-
tion [9]. Our group has previously shown MCT1 and MCT4 upregulation in a human
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series of GBM samples, being MCT1 the most prevalent plasma membrane transporter [21].
Additionally, we demonstrated that MCT1 downregulation or activity inhibition disturbs
the hyper-glycolytic phenotype of GBM cell lines [21]. Moreover, MCT1 activity has been
associated with angiogenesis [42,43], and with bevacizumab therapy response in vitro [44].
Importantly, we showed that tumour hypoxia leads to the up-regulation of MCT1, but
not of MCT4, in a series of GBM patients [23]. MCT4 has been recognized as the major
mediator of lactate efflux to the tumour microenvironment under hypoxic conditions, and
as a malignant contributor in several tumours. However, our previous studies reinforce the
importance of MCT1 as the major gatekeeper of lactate efflux in GBM, being a promising
candidate for anti-GBM therapy. In the present study, we intended to evaluate, beyond
tumour growth and aggressiveness in GBM, the prognostic value of MCT1 and its role in
the sensitivity to TMZ response in patients and also in an orthotopic xenograft GBM model.
Downregulation of MCT1 led to a decrease in glucose consumption and lactate pro-
duction, in accordance with what was previously reported in a breast cancer model [26,45],
as well as in colorectal [46] and bladder cancer [24,28] among others. Additionally, down-
regulation of MCT1 in U251 cells compromises the response to CHC and to the MCT1
specific inhibitor AR-C155858, supporting MCT1 as target of these drugs. These data
support the important role of MCT1 in the maintenance of the glycolytic phenotype of
GBM cell lines, as opposed to other studies that identify MCT4 as the most important
isoform involved in the maintenance of the glycolytic activity of tumour cells [47].
Notwithstanding, to the best of our knowledge, the prognostic value of MCT1 in GBM
has not been previously reported. Testing a large variety of independent cohorts of GBM
patients, we found high MCT1 expression is associated with a shorter OS of GBM patients.
Concordantly, we found that MCT1 downregulation in GBM is sufficient to significantly
increase the survival of mice bearing brain tumours. Together, our clinical, in vitro, and
in vivo results emphasize the role of MCT1 as a valid prognostic biomarker for GBM.
Although not yet described for GBM, few studies have explored the prognostic value of
MCT1 in other tumour types. For example, a study in bladder cancer showed that high
MCT1 expression associates with shorter OS compared with the low MCT1 expression
group [28]. Similar associations were reported in patients with endometrial cancer [48]
and clear cell renal carcinoma [49]. Beyond those described by our group in GBM [21], few
other studies have reported that inhibition of MCT1 decreases GBM cell proliferation and
invasion, promotes cell death [50,51], and increases the sensitivity to radiotherapy [52].
Further, the lower U251 shMCT1 proliferative capacity suggests that MCT1 may have
an important role in tumour growth capacity. Several studies reported the importance
of glioma stem cells on tumour initiation [53]. However, at the moment, few studies
have described the metabolic profile of glioma stem cells (GSC). A study in a murine
glioblastoma model using neural stem cells showed that these cells have the capacity of
tumour formation, and present a metabolic signature associated with a glycolytic pheno-
type with increased expression of LDHA [54]. Additionally, it was verified that these stem
cells present higher extracellular acidification than control conditions [54]. In fact, Takada
et al. showed that MCT1 is the most prevalent MCT isoform in GSC [55]. Additionally,
MCT inhibition decreases GSC proliferation, as well as sphere formation capacity in U251
cells [55]. Thus, an association of MCT1 in glioma initiation capacity could emerge as a
new hypothesis. To consolidate that, the role of MCT1 in in vitro glioma sphere formation
capacity and limiting dilution assay should be explored in the near future to support
this hypothesis.
Despite the availability of new molecular targeted therapies, the standard GBM ther-
apy remains maximal safe surgical resection, followed by radiotherapy and concomitant
chemotherapy (TMZ) [56]. The present study showed the involvement of MCT1 in the sen-
sitivity of GBM to TMZ, as MCT1 downregulation promoted an increased TMZ response
both in in vitro and in vivo models. To support the clinical translation of these findings,
in vivo combination of MCT1 targeting drugs in GBM models should be pursued, alone or
in combination with TMZ. The MCT1 inhibitor AZD3965 has been recently taken to Phase
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I/II clinical trials, for patients with advanced cancers (clinicaltrials.gov NCT01791595).
Despite the ubiquitous MCT1 expression in several human tissues, during the trials, the
drug demonstrated to be well tolerated, with nausea and fatigue being the most commonly
observed side effects [57]. An expected on-target effect was also reported in retinal function,
but changes were reversible. However, knowledge on long term effects of MCT1 inhibition
needs further investigation.
Since the activity of the DNA-repair protein MGMT is negatively associated with
TMZ sensitivity in GBM, we investigated the expression of MGMT in U251 cells upon
MCT1 silencing. Despite the decrease in MGMT transcriptional levels (RNA), we saw no
significant alterations at the protein level. Thus, this does not seem to be the mechanism by
which MCT1 downregulation boosts the effect of TMZ. Another possible mechanism could
be related with the role of MCTs in the acidification of the tumour microenvironment [58].
A decrease in TMZ IC50 for U251 shMCT1 cells, as well as an increased OS in animals
injected with U251 shMCT1 followed TMZ treatment could be partly explained by a lower
lactic acid efflux in U251 shMCT1 cells. TMZ is administered orally in patients, is stable at
acidic pH (e.g., stomach), and is spontaneously converted, at neutral or slightly basic pH
(pH~7.4) to its active metabolite 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC),
which reacts with DNA to form O6-methylguanine adducts, promoting DNA damage
and subsequent cell death [59]. Thus, the activation of TMZ may be compromised by the
acidic microenvironment created by GBM cells, which stabilizes the molecule. Therefore,
by compromising the activity of MCT1 (shMCT1), the extracellular pH of the cancer cell
would be less acidic, and this could consequently promote the conversion of the TMZ
prodrug to its active metabolite.
5. Conclusions
MCT1 is a novel biomarker of prognosis in GBM and at the same time is an attrac-
tive therapeutic target, whose downregulation prevents tumour growth, improves mice
survival, and boosts the therapeutic response to TMZ therapy.
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